Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30726182 | 0.81 | KDM4E (0.38) | GAATDP1KDM4EMAPTKMT2A | |
| SCHEMBL15541922 | 0.81 | KDM4E (0.38) | GAATDP1KDM4EMAPTKMT2A | |
| SCHEMBL3126066 | 0.81 | KDM4E (0.38) | GAATDP1KDM4EMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL15542195 | 0.79 | KDM4E (0.37) | GAATDP1KDM4EMAPTKMT2A | |
| SCHEMBL31509469 | 0.79 | KDM4E (0.41) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL3133229 | 0.78 | GAA (0.38) | GAATDP1KDM4EMAPTKMT2A | |
| SCHEMBL670428 | 0.78 | GAA (0.38) | GAATDP1KDM4EMAPTKMT2A | |
| SCHEMBL670427 | 0.78 | GAA (0.38) | GAATDP1KDM4EMAPTKMT2A | |
| SCHEMBL23358905 | 0.77 | OAT (0.38) | KDM4EKMT2ACYP2D6 | |
| SCHEMBL4264726 | 0.77 | OAT (0.38) | KDM4EKMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-03 | — | — | US | disclosed |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-03-17 | — | — | US | disclosed |
| WO-2017103188-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | NR1H4, FXR1, NR1H3 | GAA 4460/4885TDP1 3951/4885KDM4E 3881/4885 |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | NR1H4, NR1H3, NR1H2 | GAA 4605/4885TDP1 4127/4885KDM4E 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.